Active substance
Isradipine
- SFDA 3
- US FDA 5
- US price lines 2
SFDA Saudi Arabia — SFDA human drug list
| Trade name | Strength | Form · route | Pack | Public price | Type | Company | Status |
|---|---|---|---|---|---|---|---|
| LOMIR SRO CAPS 5MG | 5 mg | Capsule, hard · Oral use | 30 Blister | SAR 69.75 | NCE · Prescription | NOVARTIS | Withdrawn by MAH · Not Marketed |
| LOMIR TAB 2.5MG | 2.5 mg | Tablet · Oral use | 28 Blister | SAR 43.05 | NCE · Prescription | NOVARTIS | Withdrawn by MAH · Not Marketed |
| LOMIR TAB 2.5MG | 2.5 mg | Tablet · Oral use | 56 Blister | SAR 76.90 | NCE · Prescription | NOVARTIS | Withdrawn by MAH · Not Marketed |
US FDA United States — FDA approvals (Drugs@FDA)
| Product | Strength | Form · route | Applicant | Status | First approved |
|---|---|---|---|---|---|
| ISRADIPINE | 2.5MG; 5MG | capsule · oral | WATSON LABS TEVA | Prescription | 5 Jan 2006 |
| ISRADIPINE | 2.5MG; 5MG | capsule · oral | ELITE LABS INC | Prescription | 24 Apr 2006 |
| DYNACIRC | 2.5MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**; 5MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | capsule · oral | SMITHKLINE BEECHAM | Discontinued | 20 Dec 1990 |
| DYNACIRC CR | 5MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**; 10MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | tablet, extended release · oral | GLAXOSMITHKLINE LLC | Discontinued | 1 Jun 1994 |
| ISRADIPINE | 5MG; 10MG | tablet, extended release · oral | PHARMOBEDIENT | Discontinued | 27 Nov 2015 |
Prices — United States and England
| Source | Product as listed | Price | Unit / pack | Date |
|---|---|---|---|---|
| US NADAC | ISRADIPINE 2.5 MG CAPSULE | $1.13676 | per EA | 23 Sep 2026 |
| US NADAC | ISRADIPINE 5 MG CAPSULE | $1.70236 | per EA | 23 Sep 2026 |
NADAC: average price US retail pharmacies pay to buy the medicine. NHS Drug Tariff Part VIIIA: basic price reimbursed to pharmacies in England and Wales.
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.